Earnings ·
Bioventus reports Q3 revenue of $142.4M and EPS of $0.08 as it reviews strategic alternatives
BVSBioventus Inc.
Bioventus Inc. reported third-quarter revenue of $142.4 million, a 3% increase from the prior-year period, driven by growth in Pain Treatments. GAAP earnings per diluted share were $0.08 compared to $0.05 last year, while non-GAAP EPS rose to $0.17 from $0.15. The company generated $20.7 million in operating cash flow and made a discretionary prepayment of $15.0 million on its term loan. Bioventus reaffirmed its full-year adjusted EPS guidance of $0.75 to $0.79 per share but updated net sales guidance upward to $590–$595 million, reflecting approximately 4% to 5% growth. Management stated it continues to review potential strategic alternatives to maximize shareholder value. Bioventus is a global leader in innovations for active healing, providing products for pain treatments, surgical solutions, and restorative therapies.